AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 65(6), 2001, pp. 696-699
Copyright © 2001 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noedl, H
Right arrow Articles by Looareesuwan, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noedl, H
Right arrow Articles by Looareesuwan, S
Related Collections
Right arrow Travel Medicine
Right arrow Malaria
American Journal of Tropical Medicine and Hygiene, Vol 65, Issue 6, 696-699
Copyright © 2001 by American Society of Tropical Medicine and Hygiene

Research Articles


In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance

H Noedl, WH Wernsdorfer, S Krudsood, P Wilairatana, P Viriyavejakul, H Kollaritsch, G Wiedermann, and S Looareesuwan

Cross-resistance may be considered one of the most important factors leading to decreased drug susceptibility of Plasmodium falciparum. The study aimed to determine whether clinically relevant cross-sensitivity of P. falciparum existed between artemisinin and mefloquine. Seventy-six patients with falciparum malaria were admitted and treated with artemisinin derivatives. Treatment response parameters were assessed and in vitro drug sensitivity tests were performed with artemisinin, mefloquine, quinine, and chloroquine. Distinct in vitro cross-sensitivity between artemisinin and mefloquine was observed (p = 0.604; P < 0.001). To assess the relevance of this finding for clinical cross-resistance, we used an analytical model based on the relation of in vivo treatment response parameters (fever, parasite and symptom clearance) to a single reference drug with in vitro drug sensitivity data of several other drugs. Artemisinin (R = 0.554; P = 0.009) and mefloquine (R = 0.615; P = 0.002) in vitro drug sensitivities were equally well reflected in the in vivo treatment response to artemisinin, thereby suggesting the clinical relevance of in vitro cross-sensitivity.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. J. Bacon, C. Latour, C. Lucas, O. Colina, P. Ringwald, and S. Picot
Comparison of a SYBR Green I-Based Assay with a Histidine-Rich Protein II Enzyme-Linked Immunosorbent Assay for In Vitro Antimalarial Drug Efficacy Testing and Application to Clinical Isolates
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1172 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
H. NOEDL, M. A. FAIZ, E. B. YUNUS, M. R. RAHMAN, M. A. HOSSAIN, R. SAMAD, R. S. MILLER, L. W. PANG, and C. WONGSRICHANALAI
DRUG-RESISTANT MALARIA IN BANGLADESH: AN IN VITRO ASSESSMENT
Am J Trop Med Hyg, February 1, 2003; 68(2): 140 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Noedl, W. H. Wernsdorfer, R. S. Miller, and C. Wongsrichanalai
Histidine-Rich Protein II: a Novel Approach to Malaria Drug Sensitivity Testing
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1658 - 1664.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society of Tropical Medicine and Hygiene.